< -5%

Krishna Venture

-5% to -3%

HAMPTON SKY

-3% to 0%

Transindia Real

0% to 3%

3% to 5%

<a href="https://www.moneycontrol.com/india/stockpricequote/constructioncontracting-civil/ashokabuildcon/AB">Ashoka Buildcon</a> share price will remain in focus on February 16 following the company won road construction project in Republic of Liberia.

The company had submitted bid to the Ministry of Public Works, Liberia, for the project pf upgrading of the road from Nrowkia (Sasstown Jn) to Barclayville and Nrowkia (Sasstown Jn) to Sasstown and part of Nrowkia (Sasstown Jn) to Nipleppo road project in Republic of Liberia.

The company has received a Letter of Award for the said project at an accepted bid cost of USD 45,276,621.07, and the project is scheduled to be executed within a period of 24 months.

<a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-updates-gift-nifty-indicates-a-positive-start-us-asian-markets-mixed-liveblog-13829091.html">Catch all the market action on our live blog</a>

Earlier in this month, the company in joint venture with Aakshya Infra project received Letter of Acceptance for construction of H.L.R.C.C. bridge over river Gandak with other major bridge. The bid price for the project is Rs 474.38 crore with company holding 51% stake in the JV as lead member - partner.

Also, the company with JV partner BEC Arabia Contracting Co has received Letter of Acceptance from Diriyah Company in the Kingdom of Saudi Arabia for the project of ‘Main Construction Works of Diriyah II – Delivery Partner for One Hotel.

The accepted bid price for the project is SAR 717,086,344.22 with company's share of 49% in the JV.

The company had posted 222.6 percent surge in its quarterly net profit at Rs 2,111.41 crore in December 2025 versus Rs 654.51 crore in December 2024.

Ownership, Material Conflicts of Interest and Disciplinary History

MCD is a wholly owned subsidiary of Network 18 Media & Investments Ltd ("Network18"), in which Independent Media Trust (IMT) holds 56.89% stake. Reliance Industries Limited ("RIL") is the sole beneficiary of IMT. Network18 and RIL and their subsidiaries, joint ventures and associates can be considered as associates of MCD.

Details of Associate

Receipt of Compensation

Third-Party Compensation

Employment History

Market-Making Activities

Use of Artificial Intelligence

Ashoka Buildcon shares in focus on project win worth Rs 410 crore

Ashoka Buildcon share price will remain in focus on February 16 following the company won road construction project in Republic of Liberia.

The company had submitted bid to the Ministry of Public Works, Liberia, for the project pf upgrading of the road from Nrowkia (Sasstown Jn) to Barclayville and Nrowkia (Sasstown Jn) to Sasstown and part of Nrowkia (Sasstown Jn) to Nipleppo road project in Republic of Liberia.

The company has received a Letter of Award for the said project at an accepted bid cost of USD 45,276,621.07, and the project is scheduled to be executed within a period of 24 months.

Catch all the market action on our live blog

Earlier in this month, the company in joint venture with Aakshya Infra project received Letter of Acceptance for construction of H.L.R.C.C. bridge over river Gandak with other major bridge. The bid price for the project is Rs 474.38 crore with company holding 51% stake in the JV as lead member - partner.

Also, the company with JV partner BEC Arabia Contracting Co has received Letter of Acceptance from Diriyah Company in the Kingdom of Saudi Arabia for the project of ‘Main Construction Works of Diriyah II – Delivery Partner for One Hotel.

The accepted bid price for the project is SAR 717,086,344.22 with company's share of 49% in the JV.

The company had posted 222.6 percent surge in its quarterly net profit at Rs 2,111.41 crore in December 2025 versus Rs 654.51 crore in December 2024.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticalsdrugs/zyduslifesciences/CHC">Zydus Lifesciences</a>’ share price will remain in focus on February 16 after the company received final approval from the United States Food and Drug Administration (USFDA) for its Ammonium Lactate Cream, 12%.

Ammonium lactate cream is a topical prescription medication indicated for the treatment of dry, scaly skin (xerosis) and an inherited dry skin condition called ichthyosis vulgaris.

It is used to moisturise the skin by increasing hydration and, as an alpha-hydroxy acid, helps relieve itching, soften skin, and decrease skin scaling.

The cream will be manufactured at the group’s topical manufacturing site at Changodar, Ahmedabad, and distributed by Viona Pharmaceuticals Inc.

The group now has 430 approvals and has so far filed 505* ANDAs since the commencement of the filing process in FY 2003-04.

<a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-updates-gift-nifty-indicates-a-positive-start-us-asian-markets-mixed-liveblog-13829091.html">Catch all the market action on our live blog</a>

Last week, the company and its US subsidiary agreed to pay $120 million to Astellas Pharma as part of a settlement to resolve a patent dispute related to the Japanese drugmaker’s bladder disorder drug, Mirabegron

Zydus and its unit will also pay a pre-paid per‑unit licensing fee on sales of its generic Mirabegron in the US from the date of the agreement until September 2027, the company said.

The deal will enable the company to continue marketing its generic Mirabegron in the United States, Zydus said, adding that other terms and conditions of the agreement are confidential.

The company had reported 1.8 percent rise in December quarter net profit to Rs 1042.1 crore, while revenue from operations surged 30 percent YoY to Rs.6864.5 crore.

Zydus Lifesciences shares in focus on final nod for Ammonium Lactate Cream

Zydus Lifesciences’ share price will remain in focus on February 16 after the company received final approval from the United States Food and Drug Administration (USFDA) for its Ammonium Lactate Cream, 12%.

Ammonium lactate cream is a topical prescription medication indicated for the treatment of dry, scaly skin (xerosis) and an inherited dry skin condition called ichthyosis vulgaris.

It is used to moisturise the skin by increasing hydration and, as an alpha-hydroxy acid, helps relieve itching, soften skin, and decrease skin scaling.

The cream will be manufactured at the group’s topical manufacturing site at Changodar, Ahmedabad, and distributed by Viona Pharmaceuticals Inc.

The group now has 430 approvals and has so far filed 505* ANDAs since the commencement of the filing process in FY 2003-04.

Catch all the market action on our live blog

Last week, the company and its US subsidiary agreed to pay $120 million to Astellas Pharma as part of a settlement to resolve a patent dispute related to the Japanese drugmaker’s bladder disorder drug, Mirabegron

Zydus and its unit will also pay a pre-paid per‑unit licensing fee on sales of its generic Mirabegron in the US from the date of the agreement until September 2027, the company said.

The deal will enable the company to continue marketing its generic Mirabegron in the United States, Zydus said, adding that other terms and conditions of the agreement are confidential.

The company had reported 1.8 percent rise in December quarter net profit to Rs 1042.1 crore, while revenue from operations surged 30 percent YoY to Rs.6864.5 crore.

Stocks in focus on Feb 16:Alkem Laboratories, Zydus Lifesciences, Signature Global India, Hindustan Copper, Religare Enterprises, NLC India, National Aluminium Company, Fractal Analytics, Aye Finance

* Stocks in focus on Feb 16:Alkem Laboratories, Zydus Lifesciences, Signature Global India, Hindustan Copper, Religare Enterprises, NLC India, National Aluminium Company, Fractal Analytics, Aye Finance

shorts/business/stocks-to-watch-today-fractal-analytics-aye-manappuram-alkem-labs-zydus-life-jubilant-pharmova-fortis-healthcare-azad-engineering-precision-wires-in-focus-on-16-february

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins, and acquisitions, here’s a quick look at which stocks will be in focus in today's trade:

Quarterly Earnings

<a href="https://www.moneycontrol.com/india/stockpricequote/auto-ancillaries-brakes/olaelectricmobility/OEM">Ola Electric Mobility</a> Q3 (Consolidated YoY)

Loss narrows to Rs 487 crore Vs loss of Rs 564 crore

Revenue sinks 55% to Rs 470 crore Vs Rs 1,045 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/metals-non-ferrous/precisionwiresindia/PWI">Precision Wires India</a> Q3 (Standalone YoY)

Profit zooms 98.9% to Rs 37.7 crore Vs Rs 18.95 crore

Revenue jumps 37.2% to Rs 1,347.6 crore Vs Rs 982.3 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/aerospacedefence/azadengineering/AEL02">Azad Engineering</a> Q3 (Consolidated YoY)

Profit spikes 44.3% to Rs 34.5 crore Vs Rs 23.9 crore

Revenue grows 31.7% to Rs 158.7 crore Vs Rs 120.5 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/hospitalsmedical-services/fortishealthcare/FH">Fortis Healthcare</a> Q3 (Consolidated YoY)

Profit slips 21.9% to Rs 193.7 crore Vs Rs 247.9 crore

Revenue jumps 17.5% to Rs 2,265 crore Vs Rs 1,928.3 crore

Other income drops to Rs 8.29 crore Vs Rs 20.9 crore

Exceptional loss stands at Rs 45.91 crore Vs gain of Rs 23.8 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/travel-services/easytripplanners/ETP01">Easy Trip Planners</a> Q3 (Consolidated YoY)

Profit sinks 82.6% to Rs 5.85 crore Vs Rs 33.6 crore

Revenue rises 0.7% to Rs 151.7 crore Vs Rs 150.6 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/speciality-chemicals/anupamrasayanindia/ARI02">Anupam Rasayan India</a> Q3 (Consolidated YoY)

Profit grows 11.8% to Rs 60.6 crore Vs Rs 54.2 crore

Revenue jumps 31.3% to Rs 512.4 crore Vs Rs 390.1 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/diversified-chemicals/galaxysurfactants/GSL06">Galaxy Surfactants</a> Q3 (Consolidated YoY)

Profit falls 8.7% to Rs 59 crore Vs Rs 64.6 crore

Revenue soars 27.6% to Rs 1,329.5 crore Vs Rs 1,041.7 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/transport-infrastructure/gmrairports/GI27">GMR Airports</a> Q3 (Consolidated YoY)

Profit slips 13.9% to Rs 174 crore Vs Rs 202.1 crore

Revenue zooms 50.5% to Rs 3,994 crore Vs Rs 2,653.2 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/pumps/shaktipumpsindia/SPI08">Shakti Pumps India</a> Q3 (Consolidated YoY)

Profit tanks 69.5% to Rs 31.7 crore Vs Rs 104 crore

Revenue falls 15.1% to Rs 551 crore Vs Rs 648.8 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/finance-others/kfintechnologies/KT07">KFin Technologies</a> Q3 (Consolidated YoY)

Profit rises 2% to Rs 92 crore Vs Rs 90.2 crore

Revenue soars 27.9% to Rs 370.9 crore Vs Rs 290 crore

Labour code impact stands at Rs 8.5 crore Vs Nil

<a href="https://www.moneycontrol.com/india/stockpricequote/miningminerals/gujaratmineraldevelopmentcorporation/GMD">Gujarat Mineral Development Corporation</a> Q3 (Consolidated YoY)

Profit declines 10% to Rs 133 crore Vs Rs 147.7 crore

Revenue falls 11.4% to Rs 579.2 crore Vs Rs 653.4 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticalsdrugs/akumsdrugspharmaceuticals/ADP03">Akums Drug and Pharmaceuticals</a> Q3 (Consolidated YoY)

Profit increases 1.7% to Rs 66.3 crore Vs Rs 65.2 crore

Revenue jumps 14.8% to Rs 116 crore Vs Rs 101 crore

Other income jumps to Rs 34.3 crore Vs Rs 14.5 crore

Exceptional loss stands at Rs 18.2 crore Vs gain of Rs 4.7 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/fertilisers/nationalfertilizers/NF06">National Fertilizers</a> Q3 (Consolidated YoY)

Profit zooms 195.1% to Rs 135.2 crore Vs Rs 45.8 crore

Revenue grows 17.3% to Rs 6,869.8 crore Vs Rs 5,855.9 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/engineering/inoxgreenenergyservices/IGE01">Inox Green Energy Services</a> Q3 (Consolidated YoY)

Profit spikes 6-fold to Rs 24.7 crore Vs Rs 4.11 crore

Revenue jumps 33.8% to Rs 81.8 crore Vs Rs 61.1 crore

Other income more than doubled to Rs 29.9 crore Vs Rs 12.9 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/infrastructure-general/nbccindia/NBC01">NBCC India</a> Q3 (Consolidated YoY)

Profit soars 39.4% to Rs 193 crore Vs Rs 138.5 crore

Revenue rises 7.6% to Rs 3,022.4 crore Vs Rs 2,809 crore

Exceptional gains stand at Rs 80.1 crore Vs Nil

<a href="https://www.moneycontrol.com/india/stockpricequote/miscellaneous/crisil/CRI">CRISIL</a> Q3 (Consolidated YoY)

Profit increases 7.5% to Rs 241.5 crore Vs Rs 224.7 crore

Revenue jumps 18.5% to Rs 1,081.6 crore Vs Rs 912.9 crore

Board recommends final dividend of Rs 28 per share

<a href="https://www.moneycontrol.com/india/stockpricequote/breweriesdistilleries/tilaknagarindustries/TI09">Tilaknagar Industries</a> Q3 (Consolidated YoY)

Loss stands at Rs 105 crore Vs profit of Rs 53.9 crore

Revenue surges 80.4% to Rs 1,453 crore Vs Rs 805.3 crore

Exceptional loss stands at Rs 169.4 crore Vs Nil

<a href="https://www.moneycontrol.com/india/stockpricequote/cement-productsbuilding-materials/rhimagnesitaindia/OR01">RHI Magnesita India</a> Q3 (Consolidated YoY)

Profit grows 29.5% to Rs 61.6 crore Vs Rs 47.5 crore

Revenue rises 8% to Rs 1,092 crore Vs Rs 1,010.7 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/torrentpharmaceuticals/TP06">Torrent Pharmaceuticals</a> Q3 (Consolidated YoY)

Profit jumps 26.2% to Rs 635 crore Vs Rs 503 crore

Revenue surges 17.6% to Rs 3,303 crore Vs Rs 2,809 crore

Board announces an interim dividend of Rs 29 per share

<a href="https://www.moneycontrol.com/india/stockpricequote/transport-infrastructure/irbinfrastructuredevelopers/IID01">IRB Infrastructure Developers</a> Q3 (Consolidated YoY)

Profit sinks 96.5% to Rs 210.8 crore Vs Rs 6,026.1 crore

Revenue declines 7.6% to Rs 1,871.2 crore Vs Rs 2,025.4 crore

Exceptional loss stands at Rs 42.6 crore Vs gain of Rs 5,804.1 crore

<a href="https://www.moneycontrol.com/india/stockpricequote/packaging/epl/EP11">EPL</a> Q3 (Consolidated YoY)

Profit drops 12.6% to Rs 81.7 crore Vs Rs 93.5 crore

Revenue jumps 13.3% to Rs 1,148.8 crore Vs Rs 1,014.3 crore

Exceptional loss stands at Rs 12 crore Vs Nil

Tax expenses jump to Rs 23.7 crore Vs Rs 6.4 crore

Stocks to Watch

<a href="https://www.moneycontrol.com/india/stockpricequote/finance-leasinghire-purchase/manappuramfinance/MGF01">Manappuram Finance</a>

The Reserve Bank of India (RBI) has granted its final approval for the proposed acquisition of control and shareholding of up to 41.66% of the paid-up equity capital/convertible instruments of Manappuram Finance by BC Asia Investments XXV and BC Asia Investments XIV.

<a href="https://www.moneycontrol.com/india/stockpricequote/construction-residentialcommercial-complexes/lodhadevelopers/MD03">Lodha Developers</a>

The company has entered into a Share Purchase Agreement to acquire an 80% stake in Solidrise Realty (SRPL) for Rs 294 crore. Following this, SRPL will become a subsidiary of the company. SRPL is engaged in the real estate business in Pune.

<a href="https://www.moneycontrol.com/india/stockpricequote/oil-explorationproduction/deepindustries/DI02">Deep Industries</a>

The company has received a Letter of Award from Oil India for the hiring of a 1,000 HP mobile drilling rig package in Assam and Arunachal Pradesh. The total estimated value of the award is approximately Rs 148 crore.

<a href="https://www.moneycontrol.com/india/stockpricequote/constructioncontracting-civil/ashokabuildcon/AB">Ashoka Buildcon</a>

The company has received a Letter of Acceptance from the Ministry of Public Works, Liberia, for a project worth $45.27 million. The project involves upgrading the road from Nrowkia (Sasstown Junction) to Barclayville, Nrowkia (Sasstown Junction) to Sasstown, and part of the Nrowkia (Sasstown Junction) to Nipleppo road project in the Republic of Liberia.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/aurobindopharma/AP">Aurobindo Pharma</a>

The company’s subsidiary, Acrotech Biopharma Inc., announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ADQUEY (difamilast 1%) ointment. ADQUEY is used for the topical treatment of mild-to-moderate atopic dermatitis (AD) in adults and pediatric patients aged two years and older.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/natcopharma/NP07">Natco Pharma</a>

The company has received approval for Semaglutide from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide injection in India. Natco will launch the product in the Indian market in March 2026.

Semaglutide is used for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/jubilantpharmova/JO03">Jubilant Pharmova</a>

Jubilant HollisterStier General Partnership (JHSGP) said that the United States Food and Drug Administration (USFDA) has determined the inspection classification for the contract manufacturing facility in Montreal, Canada (CMO Montreal), as Official Action Indicated (OAI). This follows the audit of CMO Montreal conducted in October and November 2025.

The audit was reported by the company on November 4, 2025. Since then, JHSGP has been working closely with the USFDA and is committed to addressing the audit observations.

Following the implementation of robust remediation measures, production operations have resumed at the facility in Q4FY26.

JHSGP is jointly owned by subsidiaries of Jubilant Pharma, a wholly owned subsidiary of the company.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/alkemlaboratories/AL05">Alkem Laboratories</a>

The United States Food and Drug Administration (USFDA) has completed a pre-approval inspection (PAI) at the manufacturing facility of the company’s subsidiary, Enzene Biosciences. At the conclusion of the inspection, the USFDA issued a Form 483 with six procedural observations.

Enzene has achieved zero observations related to data integrity—a critical validation of Enzene’s quality systems and the reliability of regulatory filings.

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticalsdrugs/zyduslifesciences/CHC">Zydus Lifesciences</a>

The company has received final approval from the United States Food and Drug Administration (USFDA) for Ammonium Lactate Cream, 12%.

Ammonium lactate cream, 12%, is a topical prescription medication indicated for the treatment of dry, scaly skin (xerosis) and an inherited dry skin condition called ichthyosis vulgaris. It is used to moisturise the skin by increasing hydration and, as an alpha-hydroxy acid, helps relieve itching, soften the skin, and decrease skin scaling.

<a href="https://www.moneycontrol.com/india/stockpricequote/construction-real-estate/signatureglobalindia/SIL24">Signature Global (India)</a>

The company has inked an agreement to form a joint venture with RMZ, a leading developer and asset manager of commercial real estate, to develop a mixed-use project comprising office buildings, hotels, and retail spaces on the Southern Peripheral Road (SPR) in Gurugram.

Under the agreement, Signature Global and RMZ will form a 50:50 joint venture, with RMZ committing an investment of Rs 1,283 crore to acquire a 50% equity stake in the project.

Under the Securities Subscription and Purchase Agreement, RMZ will acquire a 50% equity stake in Gurugram Commercity through a combination of share purchase and share subscription for Rs 1,283 crore.

<a href="https://www.moneycontrol.com/india/stockpricequote/metals-non-ferrous/hindustancopper/HC07">Hindustan Copper</a>

The Government of Jharkhand has issued a demand notice for the recovery of a compensation amount of Rs 929.4 crore from Hindustan Copper, alleging that the company undertook production from the Surda mine without valid statutory clearances or in excess of permissible limits during the period from FY2000-01 to FY2016-17.

The company denies the allegations and is taking appropriate legal actions in this regard.

<a href="https://www.moneycontrol.com/india/stockpricequote/trading/adanienterprises/AE13">Adani Enterprises</a>

The company’s subsidiary, Horizon Aero Solutions, has completed the acquisition of 100% shareholding in Indamer Technics for Rs 330 crore. Indamer Technics has become a step-down subsidiary of the company.

The acquisition aims to expand the company’s footprint in the aircraft services and MRO industry.

<a href="https://www.moneycontrol.com/india/stockpricequote/finance-investments/religareenterprises/RE09">Religare Enterprises</a>

The boards of Religare Enterprises and Religare Finvest have approved a demerger that will segregate the company’s financial services and insurance businesses into two independent listed entities.

Under the proposed scheme of arrangement, Religare Enterprises will retain its stake in Care Health Insurance (CHIL), which will continue as an insurance-focused entity. The financial services business, comprising lending activities, broking activities, investment activities, and ancillary and support services, will be transferred to Religare Finvest on a going-concern basis.

Religare Finvest will issue fully paid-up equity shares to Religare Enterprises shareholders on a 1:1 basis. Post-demerger, Religare Finvest’s shareholding pattern will mirror Religare Enterprises’ pre-demerger shareholding.

<a href="https://www.moneycontrol.com/india/stockpricequote/power-generationdistribution/nlcindia/NLC">NLC India</a>

The company has signed a Memorandum of Understanding (MoU) with <a href="https://www.moneycontrol.com/india/stockpricequote/aluminium/nationalaluminiumcompany/NAC">National Aluminium Company</a> (NALCO) to strengthen collaboration in the development of thermal and renewable energy projects.

Bulk Deals

<a href="https://www.moneycontrol.com/india/stockpricequote/plastics/apollopipes/ALF02">Apollo Pipes</a>, <a href="https://www.moneycontrol.com/india/stockpricequote/finance-investment/sgfinserve/MS29">SG Finserve</a>

S Gupta Holding has bought 2.75 lakh shares in PVC pipes maker Apollo Pipes at Rs 317.1 per share and 2.5 lakh shares at Rs 317 per share, amounting to a 1.19% stake worth Rs 16.64 crore.

Further, promoter entity S Gupta Holding picked up 3 lakh shares (equivalent to 0.53% of paid-up equity) in SG Finserve, a non-banking finance company, at Rs 408.26 per share for Rs 12.24 crore.

<a href="https://www.moneycontrol.com/india/stockpricequote/householdpersonal-products/honasaconsumer/HCL06">Honasa Consumer</a>

Mercer QIF Fund Plc - Mercer Investment Fund 1, managed by Mercer Global Investments Management, sold 19.04 lakh shares (a 0.58% stake) in Honasa Consumer, the parent company of Mamaearth, at Rs 308.91 per share for Rs 58.82 crore.

Mainboard Listing

Fractal Analytics
Aye Finance

Stocks Trade Ex-Dividend

Apollo Hospitals Enterprise
Escorts Kubota
IIFL Capital Services
Kirloskar Ferrous Industries
Kewal Kiran Clothing
Saven Technologies
Aarti Pharmalabs
Kesar Terminals &amp; Infrastructure
Torrent Power
Uniparts India

Stocks Trade Ex-Date for Income Distribution

Anantam Highways Trust
IRB InvIT Fund

Stock Trades Ex-Date for Rights

Onelife Capital Advisors

Stocks in F&amp;O ban

SAIL
Sammaan Capital

Stocks to Watch Today: Fractal Analytics, AYE, Manappuram, Alkem Labs, Zydus Life, Jubilant Pharmova, Fortis Healthcare, Azad Engineering, Precision Wires in focus on 16 February

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins, and acquisitions, here’s a quick look at which stocks will be in focus in today's trade:

Quarterly Earnings

Ola Electric Mobility Q3 (Consolidated YoY)

Loss narrows to Rs 487 crore Vs loss of Rs 564 crore

Revenue sinks 55% to Rs 470 crore Vs Rs 1,045 crore

Precision Wires India Q3 (Standalone YoY)

Profit zooms 98.9% to Rs 37.7 crore Vs Rs 18.95 crore

Revenue jumps 37.2% to Rs 1,347.6 crore Vs Rs 982.3 crore

Azad Engineering Q3 (Consolidated YoY)

Profit spikes 44.3% to Rs 34.5 crore Vs Rs 23.9 crore

Revenue grows 31.7% to Rs 158.7 crore Vs Rs 120.5 crore

Fortis Healthcare Q3 (Consolidated YoY)

Profit slips 21.9% to Rs 193.7 crore Vs Rs 247.9 crore

Revenue jumps 17.5% to Rs 2,265 crore Vs Rs 1,928.3 crore

Other income drops to Rs 8.29 crore Vs Rs 20.9 crore

Exceptional loss stands at Rs 45.91 crore Vs gain of Rs 23.8 crore

Easy Trip Planners Q3 (Consolidated YoY)

Profit sinks 82.6% to Rs 5.85 crore Vs Rs 33.6 crore

Revenue rises 0.7% to Rs 151.7 crore Vs Rs 150.6 crore

Anupam Rasayan India Q3 (Consolidated YoY)

Profit grows 11.8% to Rs 60.6 crore Vs Rs 54.2 crore

Revenue jumps 31.3% to Rs 512.4 crore Vs Rs 390.1 crore

Galaxy Surfactants Q3 (Consolidated YoY)

Profit falls 8.7% to Rs 59 crore Vs Rs 64.6 crore

Revenue soars 27.6% to Rs 1,329.5 crore Vs Rs 1,041.7 crore

GMR Airports Q3 (Consolidated YoY)

Profit slips 13.9% to Rs 174 crore Vs Rs 202.1 crore

Revenue zooms 50.5% to Rs 3,994 crore Vs Rs 2,653.2 crore

Shakti Pumps India Q3 (Consolidated YoY)

Profit tanks 69.5% to Rs 31.7 crore Vs Rs 104 crore

Revenue falls 15.1% to Rs 551 crore Vs Rs 648.8 crore

KFin Technologies Q3 (Consolidated YoY)

Profit rises 2% to Rs 92 crore Vs Rs 90.2 crore

Revenue soars 27.9% to Rs 370.9 crore Vs Rs 290 crore

Labour code impact stands at Rs 8.5 crore Vs Nil

Gujarat Mineral Development Corporation Q3 (Consolidated YoY)

Profit declines 10% to Rs 133 crore Vs Rs 147.7 crore

Revenue falls 11.4% to Rs 579.2 crore Vs Rs 653.4 crore

Akums Drug and Pharmaceuticals Q3 (Consolidated YoY)

Profit increases 1.7% to Rs 66.3 crore Vs Rs 65.2 crore

Revenue jumps 14.8% to Rs 116 crore Vs Rs 101 crore

Other income jumps to Rs 34.3 crore Vs Rs 14.5 crore

Exceptional loss stands at Rs 18.2 crore Vs gain of Rs 4.7 crore

National Fertilizers Q3 (Consolidated YoY)

Profit zooms 195.1% to Rs 135.2 crore Vs Rs 45.8 crore

Revenue grows 17.3% to Rs 6,869.8 crore Vs Rs 5,855.9 crore

Inox Green Energy Services Q3 (Consolidated YoY)

Profit spikes 6-fold to Rs 24.7 crore Vs Rs 4.11 crore

Revenue jumps 33.8% to Rs 81.8 crore Vs Rs 61.1 crore

Other income more than doubled to Rs 29.9 crore Vs Rs 12.9 crore

NBCC India Q3 (Consolidated YoY)

Profit soars 39.4% to Rs 193 crore Vs Rs 138.5 crore

Revenue rises 7.6% to Rs 3,022.4 crore Vs Rs 2,809 crore

Exceptional gains stand at Rs 80.1 crore Vs Nil

CRISIL Q3 (Consolidated YoY)

Profit increases 7.5% to Rs 241.5 crore Vs Rs 224.7 crore

Revenue jumps 18.5% to Rs 1,081.6 crore Vs Rs 912.9 crore

Board recommends final dividend of Rs 28 per share

Tilaknagar Industries Q3 (Consolidated YoY)

Loss stands at Rs 105 crore Vs profit of Rs 53.9 crore

Revenue surges 80.4% to Rs 1,453 crore Vs Rs 805.3 crore

Exceptional loss stands at Rs 169.4 crore Vs Nil

RHI Magnesita India Q3 (Consolidated YoY)

Profit grows 29.5% to Rs 61.6 crore Vs Rs 47.5 crore

Revenue rises 8% to Rs 1,092 crore Vs Rs 1,010.7 crore

Torrent Pharmaceuticals Q3 (Consolidated YoY)

Profit jumps 26.2% to Rs 635 crore Vs Rs 503 crore

Revenue surges 17.6% to Rs 3,303 crore Vs Rs 2,809 crore

Board announces an interim dividend of Rs 29 per share

IRB Infrastructure Developers Q3 (Consolidated YoY)

Profit sinks 96.5% to Rs 210.8 crore Vs Rs 6,026.1 crore

Revenue declines 7.6% to Rs 1,871.2 crore Vs Rs 2,025.4 crore

Exceptional loss stands at Rs 42.6 crore Vs gain of Rs 5,804.1 crore

EPL Q3 (Consolidated YoY)

Profit drops 12.6% to Rs 81.7 crore Vs Rs 93.5 crore

Revenue jumps 13.3% to Rs 1,148.8 crore Vs Rs 1,014.3 crore

Exceptional loss stands at Rs 12 crore Vs Nil

Tax expenses jump to Rs 23.7 crore Vs Rs 6.4 crore

Stocks to Watch

Manappuram Finance

The Reserve Bank of India (RBI) has granted its final approval for the proposed acquisition of control and shareholding of up to 41.66% of the paid-up equity capital/convertible instruments of Manappuram Finance by BC Asia Investments XXV and BC Asia Investments XIV.

Lodha Developers

The company has entered into a Share Purchase Agreement to acquire an 80% stake in Solidrise Realty (SRPL) for Rs 294 crore. Following this, SRPL will become a subsidiary of the company. SRPL is engaged in the real estate business in Pune.

Deep Industries

The company has received a Letter of Award from Oil India for the hiring of a 1,000 HP mobile drilling rig package in Assam and Arunachal Pradesh. The total estimated value of the award is approximately Rs 148 crore.

Ashoka Buildcon

The company has received a Letter of Acceptance from the Ministry of Public Works, Liberia, for a project worth $45.27 million. The project involves upgrading the road from Nrowkia (Sasstown Junction) to Barclayville, Nrowkia (Sasstown Junction) to Sasstown, and part of the Nrowkia (Sasstown Junction) to Nipleppo road project in the Republic of Liberia.

Aurobindo Pharma

The company’s subsidiary, Acrotech Biopharma Inc., announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ADQUEY (difamilast 1%) ointment. ADQUEY is used for the topical treatment of mild-to-moderate atopic dermatitis (AD) in adults and pediatric patients aged two years and older.

Natco Pharma

The company has received approval for Semaglutide from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide injection in India. Natco will launch the product in the Indian market in March 2026.

Semaglutide is used for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

Jubilant Pharmova

Jubilant HollisterStier General Partnership (JHSGP) said that the United States Food and Drug Administration (USFDA) has determined the inspection classification for the contract manufacturing facility in Montreal, Canada (CMO Montreal), as Official Action Indicated (OAI). This follows the audit of CMO Montreal conducted in October and November 2025.

The audit was reported by the company on November 4, 2025. Since then, JHSGP has been working closely with the USFDA and is committed to addressing the audit observations.

Following the implementation of robust remediation measures, production operations have resumed at the facility in Q4FY26.

JHSGP is jointly owned by subsidiaries of Jubilant Pharma, a wholly owned subsidiary of the company.

Alkem Laboratories

The United States Food and Drug Administration (USFDA) has completed a pre-approval inspection (PAI) at the manufacturing facility of the company’s subsidiary, Enzene Biosciences. At the conclusion of the inspection, the USFDA issued a Form 483 with six procedural observations.

Enzene has achieved zero observations related to data integrity—a critical validation of Enzene’s quality systems and the reliability of regulatory filings.

Zydus Lifesciences

The company has received final approval from the United States Food and Drug Administration (USFDA) for Ammonium Lactate Cream, 12%.

Ammonium lactate cream, 12%, is a topical prescription medication indicated for the treatment of dry, scaly skin (xerosis) and an inherited dry skin condition called ichthyosis vulgaris. It is used to moisturise the skin by increasing hydration and, as an alpha-hydroxy acid, helps relieve itching, soften the skin, and decrease skin scaling.

Signature Global (India)

The company has inked an agreement to form a joint venture with RMZ, a leading developer and asset manager of commercial real estate, to develop a mixed-use project comprising office buildings, hotels, and retail spaces on the Southern Peripheral Road (SPR) in Gurugram.

Under the agreement, Signature Global and RMZ will form a 50:50 joint venture, with RMZ committing an investment of Rs 1,283 crore to acquire a 50% equity stake in the project.

Under the Securities Subscription and Purchase Agreement, RMZ will acquire a 50% equity stake in Gurugram Commercity through a combination of share purchase and share subscription for Rs 1,283 crore.

Hindustan Copper

The Government of Jharkhand has issued a demand notice for the recovery of a compensation amount of Rs 929.4 crore from Hindustan Copper, alleging that the company undertook production from the Surda mine without valid statutory clearances or in excess of permissible limits during the period from FY2000-01 to FY2016-17.

The company denies the allegations and is taking appropriate legal actions in this regard.

Adani Enterprises

The company’s subsidiary, Horizon Aero Solutions, has completed the acquisition of 100% shareholding in Indamer Technics for Rs 330 crore. Indamer Technics has become a step-down subsidiary of the company.

The acquisition aims to expand the company’s footprint in the aircraft services and MRO industry.

Religare Enterprises

The boards of Religare Enterprises and Religare Finvest have approved a demerger that will segregate the company’s financial services and insurance businesses into two independent listed entities.

Under the proposed scheme of arrangement, Religare Enterprises will retain its stake in Care Health Insurance (CHIL), which will continue as an insurance-focused entity. The financial services business, comprising lending activities, broking activities, investment activities, and ancillary and support services, will be transferred to Religare Finvest on a going-concern basis.

Religare Finvest will issue fully paid-up equity shares to Religare Enterprises shareholders on a 1:1 basis. Post-demerger, Religare Finvest’s shareholding pattern will mirror Religare Enterprises’ pre-demerger shareholding.

NLC India

The company has signed a Memorandum of Understanding (MoU) with National Aluminium Company (NALCO) to strengthen collaboration in the development of thermal and renewable energy projects.

Bulk Deals

Apollo Pipes, SG Finserve

S Gupta Holding has bought 2.75 lakh shares in PVC pipes maker Apollo Pipes at Rs 317.1 per share and 2.5 lakh shares at Rs 317 per share, amounting to a 1.19% stake worth Rs 16.64 crore.

Further, promoter entity S Gupta Holding picked up 3 lakh shares (equivalent to 0.53% of paid-up equity) in SG Finserve, a non-banking finance company, at Rs 408.26 per share for Rs 12.24 crore.

Honasa Consumer

Mercer QIF Fund Plc - Mercer Investment Fund 1, managed by Mercer Global Investments Management, sold 19.04 lakh shares (a 0.58% stake) in Honasa Consumer, the parent company of Mamaearth, at Rs 308.91 per share for Rs 58.82 crore.

Mainboard Listing

Fractal Analytics
Aye Finance

Stocks Trade Ex-Dividend

Apollo Hospitals Enterprise
Escorts Kubota
IIFL Capital Services
Kirloskar Ferrous Industries
Kewal Kiran Clothing
Saven Technologies
Aarti Pharmalabs
Kesar Terminals &amp;amp; Infrastructure
Torrent Power
Uniparts India

Stocks Trade Ex-Date for Income Distribution

Anantam Highways Trust
IRB InvIT Fund

Stock Trades Ex-Date for Rights

Onelife Capital Advisors

Stocks in F&amp;amp;O ban

SAIL
Sammaan Capital

S Gupta Holding picks up 1.2% stake in Apollo Pipes, S Gupta Holding buys 0.53% shares in SG Finserve, Mercer Global Investments Management sells 0.58% stake in Honasa Consumer

* S Gupta Holding picks up 1.2% stake in Apollo Pipes
* S Gupta Holding buys 0.53% shares in SG Finserve
* Mercer Global Investments Management sells 0.58% stake in Honasa Consumer

shorts/business/s-gupta-holding-picks-up-1-2-stake-in-apollo-pipes-0-53-shares-in-sg-finserve

* S Gupta Holding picks up 1.2% stake in Apollo Pipes
* S Gupta Holding buys 0.53% shares in SG Finserve
* Mercer Global Investments Management sells 0.58% stake in Honasa Consumer

S Gupta Holding on February 13 has acquired 1.2 percent equity stake in Apollo Pipes, and additional 0.53 percent shares in SG Finserve via open market transactions.

<a href="https://www.moneycontrol.com/india/stockpricequote/plastics/apollopipes/ALF02">Apollo Pipes</a> shares rose 1.29 percent to Rs 319.05, while <a href="https://www.moneycontrol.com/india/stockpricequote/finance-investment/sgfinserve/MS29">SG Finserve</a> stock fell 2.18 percent to Rs 405.4 after couple of day of correction.

S Gupta Holding has bought 2.75 lakh shares in PVC pipes maker Apollo Pipes at Rs 317.1 per share, and 2.5 lakh shares at Rs 317 per share, totalling to 1.19 percent stake worth Rs 16.64 crore.

Further, promoter entity S Gupta Holding picked up 3 lakh shares (equivalent to 0.53 percent of paid-up equity) in SG Finserve, the non-banking finance company, at Rs 408.26 per share for Rs 12.24 crore.

Meanwhile, Mercer QIF Fund Plc - Mercer Investment Fund 1, managed by Mercer Global Investments Management, sold 19.04 lakh shares (0.58 percent stake) in <a href="https://www.moneycontrol.com/india/stockpricequote/householdpersonal-products/honasaconsumer/HCL06">Honasa Consumer</a>, the parent company of Mamaearth, at Rs 308.91 per share for Rs 58.82 crore. However, the stock rose 0.74 percent to finish at Rs 301.45.

<img class="alignnone size-full wp-image-13829080 aligncenter" src="https://images.moneycontrol.com/static-mcnews/2026/02/20260215195617_Image3515022026.jpg" alt="Image3515022026" width="700" height="1450" />

S Gupta Holding picks up 1.2% stake in Apollo Pipes, 0.53% shares in SG Finserve

S Gupta Holding on February 13 has acquired 1.2 percent equity stake in Apollo Pipes, and additional 0.53 percent shares in SG Finserve via open market transactions.

Apollo Pipes shares rose 1.29 percent to Rs 319.05, while SG Finserve stock fell 2.18 percent to Rs 405.4 after couple of day of correction.

S Gupta Holding has bought 2.75 lakh shares in PVC pipes maker Apollo Pipes at Rs 317.1 per share, and 2.5 lakh shares at Rs 317 per share, totalling to 1.19 percent stake worth Rs 16.64 crore.

Further, promoter entity S Gupta Holding picked up 3 lakh shares (equivalent to 0.53 percent of paid-up equity) in SG Finserve, the non-banking finance company, at Rs 408.26 per share for Rs 12.24 crore.

Meanwhile, Mercer QIF Fund Plc - Mercer Investment Fund 1, managed by Mercer Global Investments Management, sold 19.04 lakh shares (0.58 percent stake) in Honasa Consumer, the parent company of Mamaearth, at Rs 308.91 per share for Rs 58.82 crore. However, the stock rose 0.74 percent to finish at Rs 301.45.

Bank Nifty slipped 1 percent with 11 of 14 stocks ending lower., Canara Bank fell 2 percent, PNB and HDFC Bank also declined., Key support for Bank Nifty seen at 59,700, resistance at 61,000.

* Bank Nifty slipped 1 percent with 11 of 14 stocks ending lower.
* Canara Bank fell 2 percent, PNB and HDFC Bank also declined.
* Key support for Bank Nifty seen at 59,700, resistance at 61,000.

Bank Nifty fell 0.9% amid profit booking and weak markets, with 11 of 14 constituents declining. Canara Bank led losses, followed by PNB and HDFC Bank. Technical analysts see key support near 59,700 and resistance at 60,800–61,000. IT stocks also dragged benchmarks lower.

shorts/business/bank-nifty-declines-0-9-on-profit-booking-canara-bank-pnb-lead-losses-check-key-trading-levels

* Bank Nifty slipped 1 percent with 11 of 14 stocks ending lower.
* Canara Bank fell 2 percent, PNB and HDFC Bank also declined.
* Key support for Bank Nifty seen at 59,700, resistance at 61,000.

The Bank Nifty extended losses in Friday’s session, slipping about 0.9 percent amid profit booking in a weak broader market.

Eleven of the 14 constituents ended lower.

Shares of <a href="https://www.moneycontrol.com/india/stockpricequote/banks-public-sector/canarabank/CB06">Canara Bank</a> declined up to 2 percent to emerge the top loser. <a href="https://www.moneycontrol.com/india/stockpricequote/banks-public-sector/punjabnationalbank/PNB05">Punjab National Bank</a> and HDFC Bank fell 1.9 percent and 1.8 percent, respectively.

Other major laggards included Axis Bank, ICICI Bank, Kotak Mahindra Bank and AU Small Finance Bank, which declined up to 1 percent.

Sudeep Shah, Head – Technical and Derivatives Research at SBI Securities, said the index had traded within a 431-point range over the last four sessions and has now broken below the lower end of the consolidation zone.

"The breakdown was accompanied by a bearish daily candle. RSI, which had plateaued near 60, has started turning down, suggesting bulls are losing grip around the key support area," he said.

According to him, immediate support is placed in the 20-day EMA zone of 60,000–59,900. A sustained move below this area could push the index towards 59,500, followed by 59,000 in the short term, while 60,500–60,600 may act as immediate resistance.

Vatsal Bhuva, Technical Analyst at LKP Securities, said the index slipped below a short-term consolidation range, indicating minor profit booking after the recent upmove.

He added the index continues to trade above its 20-day moving average near 59,700, which remains a key support. Immediate support is seen in the 59,800–59,700 zone, with a stronger base at 58,800–58,700. Resistance is placed near 60,800–61,000.

The decline in Bank Nifty tracked weakness in the broader market.

The equity benchmarks traded with a negative bias through the day as selling in information technology (IT) stocks intensified. After a weak start, the market moved in a narrow range during the first half before losses deepened later. The benchmark index settled near the day’s low at 25,471.10, with selling seen across sectors, particularly IT, along with metal, realty and FMCG stocks.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

A financial journalist with over 10 years of experience, specialising in tracking stock market movements and fundamental developments that impact investors and the broader economy. A keen observer of global financial markets, I regularly engage with leading market voices to write stories. At Moneycontrol, I focus on decoding market trends, policy shifts and economic changes, driven by a constant passion to learn, analyse, and share knowledge with my readers.

Bank Nifty declines 0.9% on profit booking; Canara Bank, PNB lead losses: Check key trading levels

The Bank Nifty extended losses in Friday’s session, slipping about 0.9 percent amid profit booking in a weak broader market.

Eleven of the 14 constituents ended lower.

Shares of Canara Bank declined up to 2 percent to emerge the top loser. Punjab National Bank and HDFC Bank fell 1.9 percent and 1.8 percent, respectively.

Other major laggards included Axis Bank, ICICI Bank, Kotak Mahindra Bank and AU Small Finance Bank, which declined up to 1 percent.

Sudeep Shah, Head – Technical and Derivatives Research at SBI Securities, said the index had traded within a 431-point range over the last four sessions and has now broken below the lower end of the consolidation zone.

&quot;The breakdown was accompanied by a bearish daily candle. RSI, which had plateaued near 60, has started turning down, suggesting bulls are losing grip around the key support area,&quot; he said.

According to him, immediate support is placed in the 20-day EMA zone of 60,000–59,900. A sustained move below this area could push the index towards 59,500, followed by 59,000 in the short term, while 60,500–60,600 may act as immediate resistance.

Vatsal Bhuva, Technical Analyst at LKP Securities, said the index slipped below a short-term consolidation range, indicating minor profit booking after the recent upmove.

He added the index continues to trade above its 20-day moving average near 59,700, which remains a key support. Immediate support is seen in the 59,800–59,700 zone, with a stronger base at 58,800–58,700. Resistance is placed near 60,800–61,000.

The decline in Bank Nifty tracked weakness in the broader market.

The equity benchmarks traded with a negative bias through the day as selling in information technology (IT) stocks intensified. After a weak start, the market moved in a narrow range during the first half before losses deepened later. The benchmark index settled near the day’s low at 25,471.10, with selling seen across sectors, particularly IT, along with metal, realty and FMCG stocks.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Real Estate Operations Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Real Estate Operations industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q3 FY25-26

Stock News

Ashoka Buildcon shares in focus on project win worth Rs 410 crore

Zydus Lifesciences shares in focus on final nod for Ammonium Lactate Cream

Stocks to Watch Today: Fractal Analytics, AYE, Manappuram, Alkem Labs, Zydus Life, Jubilant Pharmova, Fortis Healthcare, Azad Engineering, Precision Wires in focus on 16 February

S Gupta Holding picks up 1.2% stake in Apollo Pipes, 0.53% shares in SG Finserve

Bank Nifty declines 0.9% on profit booking; Canara Bank, PNB lead losses: Check key trading levels

Real Estate Operations Industry StocksCheck latest stock performance, list of stocks, earnings review & more details about the Real Estate Operations industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q3 FY25-26

Stock News

Ashoka Buildcon shares in focus on project win worth Rs 410 crore

Zydus Lifesciences shares in focus on final nod for Ammonium Lactate Cream

Stocks to Watch Today: Fractal Analytics, AYE, Manappuram, Alkem Labs, Zydus Life, Jubilant Pharmova, Fortis Healthcare, Azad Engineering, Precision Wires in focus on 16 February

S Gupta Holding picks up 1.2% stake in Apollo Pipes, 0.53% shares in SG Finserve

Bank Nifty declines 0.9% on profit booking; Canara Bank, PNB lead losses: Check key trading levels

Real Estate Operations Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Real Estate Operations industry stocks.